R & D Center

Ut ad augendae facultatem investigationis et progressionem in
PHARMACEUTICICUS industria, nostra societas est superbus est nuntiare constructione de novo productio basi. Et productionem basi operientes a totalis area CL m, cum constructione investment de 800,000 Yuan. Et aedificavit (V) D quadratum metris de R & D centrum, est in operationem.

In instauratione R & D centro marcas a significant emendationem in turma scriptor scientificam investigationis fortitudinem in agro medicina. Currently, habemus summus gradu investigationis et progressionem dolor composito ex CL professional et technels. Sunt dicata ad investigationem et productionem series nucleoside monomers, ADC payloads, linker key intermedia, aedificationem obstructionum consuetudinem synthesis, parva moleculae CDMo servicia, et magis.

Nostra ultima metam est ad auxilium accelerare usque ad launch of novus medicinae et amplio qualitas vitae pro aegris terrarum. Per leveraging continuam technicae innovation et viridi pharmaceutical exercitia, nos potest providere unum-subsisto CMC officiis ut tam domesticis et externis pharmaceutical societates, assistentes cum omni scaena in pharmacecle ex progressionem ad applicationem.

We understand that cost-effectiveness is critical for our customers, which is why we use sustainable and efficient production methods like continuous reactions and enzymatic catalysis to reduce costs and drive sustainable growth in orders. Nostra commitment ad qualis, innovation, et sustineri sets nos seorsum ut princeps in pharmaceutical industria et clavis socium in global quest ad melius curis eventus.